# Hyperkalemia Emergency Treatment

Treat hyperkalemia as an electrical emergency when potassium exceeds 6.0 mmol/L or ECG toxicity is present: monitor, stabilize myocardium with IV calcium, shift potassium intracellularly, remove total-body potassium, and reassess for rebound or dialysis need.

**Clinical question:** How should physicians stabilize, temporize, definitively remove potassium, and monitor adults with acute hyperkalemia?

Updated: 2026-09-15T21:46:42.940213+00:00

## What matters in practice
- Obtain a 12-lead ECG and institute cardiac monitoring when potassium is greater than 6.0 mmol/L; ECG changes or severe potassium elevation warrant immediate treatment rather than waiting for repeat confirmation. [6][7][8]
- Give IV calcium immediately for hyperkalemia-associated ECG abnormalities; calcium stabilizes cardiac excitability but does not lower serum potassium. [8][12]
- For intracellular redistribution, IV regular insulin 5 units with 25 g glucose and nebulized albuterol 10 mg are supported acute options and may have additive potassium-lowering effects. [12]
- Check glucose serially after insulin, especially in kidney failure; hypoglycemia after insulin-dextrose has been reported despite concomitant dextrose and monitoring for at least 3 hours is supported in ESRD. [13][14]
- Definitive potassium removal requires renal excretion, gastrointestinal binding, or hemodialysis; hemodialysis is the preferred and most effective urgent elimination method when indicated. [11][12][18]

## Identify patients requiring monitored emergency treatment

Use potassium concentration, electrical toxicity, and clinical context to determine urgency.

Place patients with potassium greater than 6.0 mmol/L on continuous cardiac monitoring and obtain a 12-lead ECG. Refer patients with potassium greater than 6.0 mmol/L or any hyperkalemia-associated ECG change to an emergency setting capable of immediate monitored treatment. [6][7][8]

Do not use a normal ECG to exclude clinically consequential hyperkalemia. Reported manifestations include peaked T waves, PR prolongation, P-wave flattening, QRS widening, and ventricular fibrillation, but ECG changes need not progress sequentially and ventricular fibrillation can occur without preceding classic findings. [8]

Repeat potassium promptly when hemolysis, collection artifact, or pseudohyperkalemia is plausible, but do not allow confirmation to delay therapy in a patient with potassium greater than 6.0 mmol/L plus ECG toxicity or clinical instability. Obtain rapid biochemical confirmation and assess for acute kidney injury, chronic kidney disease, end-stage kidney disease, metabolic acidosis, diabetes, heart failure, and medication contributors. [7][8][9]
- Treat the ECG, not a potassium value alone: new conduction delay, bradyarrhythmia, QRS widening, or ventricular dysrhythmia requires immediate membrane stabilization. [8][12]
- Review ACE inhibitor, ARB, potassium-sparing diuretic, and other potassium-raising exposures while assessing renal function and ongoing potassium burden. [9]
- If emergent hyperkalemia prompts temporary interruption of a renin-angiotensin system inhibitor, plan reassessment and reinitiation after resolution when the original indication remains present. [5]

*Initial emergency actions are driven by potassium greater than 6.0 mmol/L, ECG findings, and ability to remove potassium. [6][7][8][12]*

| Finding | Immediate action | What it changes |
| --- | --- | --- |
| Potassium >6.0 mmol/L | Continuous cardiac monitoring and 12-lead ECG. [6][8] | Identifies electrical toxicity and need for immediate stabilization. [8] |
| ECG changes attributable to hyperkalemia | Give IV calcium immediately, then initiate potassium redistribution and removal. [8][12] | Calcium addresses imminent cardiac conduction risk but does not eliminate potassium. [8] |
| Hemolyzed or discordant potassium result without instability | Repeat biochemical potassium measurement while evaluating pseudohyperkalemia. [7][8] | Avoids treating a spurious result; do not delay treatment when ECG toxicity is present. [7][8] |
| Severely impaired kidney function or absent effective excretion | Arrange hemodialysis early while temporizing measures are administered. [10][11][12] | Dialysis provides definitive, most effective potassium elimination. [11][12] |

## Use IV calcium for hyperkalemic ECG abnormalities

Calcium is the first medication when hyperkalemia is producing electrical instability.

Administer IV calcium immediately when hyperkalemia-associated ECG changes are present. The KDIGO emergency algorithm lists either calcium gluconate 1 g IV, repeatable up to three 1-g doses using 10 mL of 10% solution per dose, or calcium chloride 1 g IV using 10 mL of 10% solution. [8][12]

Select calcium as myocardial protection while concurrently initiating therapies that shift and remove potassium. It is not a potassium-lowering therapy; failure to pair calcium with redistribution and elimination permits recurrent electrical toxicity as serum potassium remains elevated. [8][12]
- Use calcium gluconate 1 g IV as a listed emergency regimen; the referenced algorithm permits up to three sequential 1-g doses. [12]
- Calcium chloride 1 g IV is an alternative listed in the same algorithm. [12]
- Continue ECG monitoring after calcium because potassium-associated conduction abnormalities may recur until potassium is redistributed and definitively removed. [8][12]

*IV calcium regimens for hyperkalemia-associated ECG toxicity. [12]*

| Agent | Listed IV dose | Clinical role |
| --- | --- | --- |
| Calcium gluconate | 1 g IV; algorithm lists up to 3 doses of 1 g, each as 10 mL of 10% solution. [12] | Immediate myocardial membrane stabilization in ECG-toxic hyperkalemia. [8][12] |
| Calcium chloride | 1 g IV, 10 mL of 10% solution. [12] | Alternative calcium preparation for immediate myocardial membrane stabilization. [12] |

## Shift potassium intracellularly while arranging elimination

Redistribution buys time; it does not reduce total-body potassium.

Use IV regular insulin with dextrose as a principal rapid intracellular-shift therapy. A KDIGO emergency regimen is regular insulin 5 units IV plus 25 g glucose IV; other guideline-referenced regimens use 5 to 10 units of IV insulin with 25 to 50 g dextrose. [12][14] A commonly used alternative is 10 units of regular insulin IV with 25 g dextrose. [13]

Add nebulized albuterol 10 mg when further rapid redistribution is needed and no patient-specific concern precludes beta-agonist use. Insulin and albuterol may have additive effects, although albuterol is ineffective in some patients; expected adverse effects include tremor, palpitations, headache, and mild hyperglycemia. [11][12]

Reserve IV sodium bicarbonate for patients with concomitant metabolic acidosis rather than routine use in normoacidic hyperkalemia. The KDIGO algorithm lists 50 mmol IV over 15 minutes; bicarbonate has little potassium-lowering effect without acidosis and is not indicated as routine acute therapy. [11][12][18]
- Check bedside glucose before IV insulin and serially afterward; kidney dysfunction increases concern for delayed hypoglycemia. [13][14]
- In ESRD, provide dextrose support and monitor glucose for at least 3 hours after insulin-based treatment. [13]
- Do not regard insulin, albuterol, or bicarbonate as definitive therapy; each acts by transcellular redistribution and must be followed by a potassium-removal plan. [18][20]

### Prevent and detect insulin-associated hypoglycemia

Hypoglycemia is a major treatment complication after insulin-dextrose, particularly in reduced kidney function. Published incidence estimates vary from 6.1% to 75%, and one ESRD study reported blood glucose below 55 mg/dL at 1 hour in 9 of 12 patients receiving 10 units of IV regular insulin with 25 g dextrose. [13][14]
- Use serial glucose measurements after insulin rather than a single post-treatment value. [8][13][14]
- Maintain at least 3 hours of glucose monitoring in ESRD after insulin treatment. [13]

*Temporizing potassium-shift therapies and their key limitations. [11][12][13][14][18]*

| Therapy | Supported regimen | Selection and monitoring |
| --- | --- | --- |
| Regular insulin plus glucose | Regular insulin 5 units IV plus glucose 25 g IV; guidelines cited elsewhere describe 5-10 units with 25-50 g dextrose. [12][14] | Use for rapid redistribution; measure glucose serially because hypoglycemia is common, particularly with reduced kidney function. [13][14] |
| Nebulized albuterol | 10 mg nebulized. [12] | Can be combined with insulin for additive effect; recognize occasional nonresponse and beta-agonist adverse effects. [11][12] |
| Sodium bicarbonate | 50 mmol IV over 15 minutes in the KDIGO algorithm. [12] | Reserve for coexisting metabolic acidosis; it has limited effect without acidosis. [11][18] |

## Remove potassium and escalate early to hemodialysis when needed

A successful emergency plan includes a route for total-body potassium elimination.

Hemodialysis is the preferred and most effective method of urgent potassium elimination. Arrange it early for severe hyperkalemia when kidney function is too poor for meaningful renal potassium excretion, when hyperkalemia persists despite medical management, or when recurrent elevation is expected while temporizing therapies wear off. [10][11][12]

If the patient has sufficient kidney function, loop diuretics can support urinary potassium removal; their utility depends on preserved renal function. [10][18] Correct the precipitating process that is limiting potassium excretion or creating ongoing release, including acute kidney injury, chronic kidney disease, metabolic acidosis, and potassium-raising medication combinations. [9][18]

Gastrointestinal binders may contribute to potassium elimination but should not replace immediate calcium, insulin-dextrose, albuterol, or dialysis planning in ECG-toxic hyperkalemia. The KDIGO algorithm lists sodium polystyrene sulfonate 15 to 60 g orally or rectally without sorbitol and sodium zirconium cyclosilicate 10 g orally three times daily; it states that patiromer is not advisable for emergency use because onset is approximately 7 hours. [12]
- Avoid sodium polystyrene sulfonate with sorbitol; the agent has been associated with rare gastrointestinal toxicity and long-term use is poorly tolerated. [12][18]
- Use binders as adjunctive elimination therapy only after determining whether dialysis is required. [11][12]
- When an ACE inhibitor or ARB was held for emergent hyperkalemia, reassess and restart after the adverse event resolves when clinically indicated rather than leaving the patient indefinitely without disease-modifying therapy. [5]

*Potassium-elimination options after emergency stabilization. [10][11][12][18]*

| Method | When to use | Key limitation or instruction |
| --- | --- | --- |
| Hemodialysis | Severe or persistent hyperkalemia with inadequate renal elimination or need for urgent definitive removal. [10][11][12] | Most effective and preferred urgent elimination modality; arrange while medical temporizing therapy is underway. [11][12] |
| Loop diuretic | Patient has reasonable kidney function and capacity for urinary potassium excretion. [10][18] | Not a reliable sole strategy when renal function is severely impaired. [10] |
| Sodium polystyrene sulfonate | Adjunctive gastrointestinal potassium removal; KDIGO algorithm lists 15-60 g orally or rectally. [12] | Do not administer with sorbitol; gastrointestinal toxicity is a recognized concern. [12][18] |
| Sodium zirconium cyclosilicate | Adjunctive gastrointestinal potassium removal; KDIGO algorithm lists 10 g orally three times daily. [12] | Limited emergency-onset data and no head-to-head binder data in the cited algorithm. [12] |
| Patiromer | More relevant to ongoing potassium management than immediate electrical emergencies. [18] | Not advisable for emergency treatment in the KDIGO algorithm because onset is approximately 7 hours. [12] |

## Recheck potassium, glucose, ECG status, and definitive elimination

Monitoring must detect recurrent electrical toxicity, treatment complications, and rebound hyperkalemia.

Reevaluate serum potassium frequently after treatment to document response and identify recurrence after redistribution therapy. Continue cardiac monitoring until the acute electrical risk has resolved and a durable potassium-elimination strategy is in place. [8][12]

After IV insulin, use serial glucose testing because hypoglycemia can occur despite dextrose coadministration and may be delayed in ESRD or reduced kidney function. In ESRD, monitor for at least 3 hours after insulin treatment. [13][14]

Before disposition, establish why potassium rose and whether potassium can be eliminated without dialysis. Patients with persistent severe elevation, ECG abnormalities, inadequate renal clearance, or need for urgent dialysis require continued monitored care rather than discharge after a transient laboratory improvement. [7][8][11][12]
- Repeat potassium after temporizing treatment and after definitive removal to detect rebound. [8][12][14]
- Reassess acid-base status when bicarbonate was used; its acute role is linked to concomitant metabolic acidosis. [11][18]
- Reconcile potassium-raising medications and plan follow-up for reintroduction of indicated renin-angiotensin system inhibition after the emergency resolves. [5][9]

*Post-treatment monitoring targets for emergency hyperkalemia. [8][12][13][14]*

| Parameter | Monitoring action | Action if abnormal |
| --- | --- | --- |
| ECG and rhythm | Continue cardiac monitoring after potassium greater than 6.0 mmol/L or ECG toxicity. [6][8] | Recurrent conduction abnormality or dysrhythmia requires repeat immediate stabilization and escalation of potassium removal. [8][12] |
| Serum potassium | Recheck frequently after treatment. [8] | Persistent or recurrent elevation requires reassessment of ongoing source and definitive removal, including hemodialysis when indicated. [11][12] |
| Blood glucose | Obtain serial measurements after IV insulin; monitor at least 3 hours in ESRD. [13][14] | Treat hypoglycemia promptly and continue surveillance because impaired kidney function increases risk. [13][14] |

## Common questions

### Should a normal ECG delay emergency treatment of severe hyperkalemia?

No. ECG abnormalities are an important marker of electrical toxicity, but hyperkalemia can progress to ventricular fibrillation without sequential classic ECG changes. In a patient with potassium greater than 6.0 mmol/L and concerning clinical context, use monitoring, repeat biochemical testing when appropriate, and do not delay treatment for confirmation if instability or ECG toxicity is present. [7][8]

### Is sodium bicarbonate routine treatment for acute hyperkalemia?

No. Reserve IV bicarbonate for coexisting metabolic acidosis after immediate membrane stabilization and potassium-shift therapy; without acidosis, bicarbonate lowers potassium only slightly. The KDIGO algorithm lists 50 mmol IV over 15 minutes. [11][12][18]

## References
1. Hyperkalemia in adults - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/3000318
2. Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S104366181630723X
3. An Evidence-Based Narrative Review of the Emergency Department Management of Acute Hyperkalemia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467920313299
4. Hyperkalemia management in the emergency department: An expert panel consensus — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2688115224009871
5. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253820312709
6. Acute hyperkalemia in the emergency department - Ovid — journals.lww.com — https://journals.lww.com/euro-emergencymed/fulltext/2020/10000/acute_hyperkalemia_in_the_emergency_department__a.10.aspx
7. Recent Advances in Nephrology: The Research Gaps... : Nigerian Journal of Clinical Practice — journals.lww.com — https://journals.lww.com/njcp/_layouts/15/oaks.journals/downloadpdf.aspx?an=01253091-202502000-00001
8. Acute hyperkalemia in adults : Turkish Journal of Emergency Medicine — journals.lww.com — https://journals.lww.com/tjem/_layouts/15/oaks.journals/downloadpdf.aspx?an=01949575-202323020-00002
9. EMCREG-International Multidisciplinary Consensus... : Cardiorenal Medicine — journals.lww.com — https://journals.lww.com/01642367-202515010-00011
10. [PDF] Kidney News - May 2010 - American Society of Nephrology — www.asn-online.org — https://www.asn-online.org/publications/kidneynews/archives/2010/KN_2010_05_may.pdf
11. Hyperkalemia management in the emergency department - PMC - NIH — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8485984
12. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7448835
13. Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4377748
14. Hyperkalemia Management with Intravenous Insulin in Patients with Reduced Kidney Function - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11396335
15. Third in a series on hyperkalemia: current views on the treatment of hyperkalemia — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-14/fourteen-thirteen
16. [PDF] Summary form National Institute for Health and Care Excellence ... — www.nice.org.uk — https://www.nice.org.uk/guidance/ta623/documents/draft-scope-and-provisional-matrix-comments-table-post-referral
17. Hyperkalaemia | Treatment summaries - BNF - NICE — bnf.nice.org.uk — https://bnf.nice.org.uk/treatment-summaries/hyperkalaemia
18. Diagnosis and treatment of hyperkalemia — www.ccjm.org — https://www.ccjm.org/content/84/12/934
19. [PDF] ACE inhibitors and ARBs: Managing potassium and renal function — www.ccjm.org — https://www.ccjm.org/sites/default/files/additional-assets/PDFs/Current_Drug_Therapy_Example.pdf
20. Treatment of hyperkalemia: something old, something new — www.kidney-international.org — https://www.kidney-international.org/article/S0085-2538(15)00123-4/fulltext
21. A phase 2 study on the treatment of hyperkalemia in patients with ... — www.kidney-international.org — https://www.kidney-international.org/article/S2157-1716(15)32161-4/pdf
22. Clinical Management of Hyperkalemia - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0025619620306182
23. Review Treatment of hyperkalemia: something old, something new — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253815001234
24. Sodium bicarbonate administration and subsequent potassium concentration in hyperkalemia treatment — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0735675721005982

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.